· Intro
· Factors increasing rate of uptake
· Logistics: pros and cons
· Kinetics: pros and cons
Definition |
Absorbed through the skin |
Path of drug |
Patch -> epidermis -> dermis -> blood vessel Multiple lipid membranes |
Locally acting |
Lignocaine/prilocaine, amethocaine |
Systemically acting |
Fentanyl, buprenorphine, GTN, nicotine |
Fick’s law of diffusion |
|
↑C1 |
e.g. lignocaine 2% cf. 1% e.g. EMLA eutectic mix 1:1 -> mutual liquid dissolution -> allows high concentration (2.5% ea) |
↓C2 |
↑Tissue blood flow rate (note slow if hypovolaemia, hypothermia) |
↑Area |
↑Patch area |
↓Thickness |
Flexor skin (e.g. abdomen) cf. extensor skin (back) (note epidermis 0.5centimetre cf. lung 0.5micrometre) |
↑Lipid solubility |
e.g. fentanyl 600x morphine 1x |
↓Molecular weight |
The ‘500 Dalton rule’ e.g. amethocaine 264 Da |
↑%Unionised |
e.g. amethocaine: 40%, highest of all local anaesthetics e.g. EMLA: added OH -> ↑pH -> ↑%unionised lignocaine and prilocaine |
Pros |
Cons |
Painless |
Risk of inadvertent removal |
Non-invasive |
Often hidden |
Convenient |
Risk of adverse reaction to carrier |
Pros |
Cons |
Not reliant on gut absorption |
Slow and variable onset, long time to peak effect Risk of dose stacking and toxicity e.g. >24 hours for fentanyl |
No first pass hepatic metabolism |
Slow offset -> long duration of toxicity (e.g. >24h for fentanyl) |
High bioavailability e.g. GTN near 100% cf. oral near 0% |
|
Constant plasma concentration once at steady state Quasi IV infusion |
|
Slow offset -> infrequent dosing e.g. buprenorphine 7 days |
|
Feedback welcome at ketaminenightmares@gmail.com